Albiges L et al. Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study. ASCO 2023;Abstract 4553.
Albiges L et al. Phase II KEYNOTE-B61 study of pembrolizumab (pembro) + lenvatinib (lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). ESMO 2022;Abstract 1448O.
Allaf et al. Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. ESMO 2022;Abstract LBA67.
Atkins MB et al. Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC. Genitourinary Cancers Symposium 2022;Abstract 362.
Burotto et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. Genitourinary Cancers Symposium 2023;Abstract 603.
Cella D et al. Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial. ASCO 2023;Abstract 4527.
Choueiri TK et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med 2023;388(19):1767-78. Abstract
Choueiri TK et al. Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study. ASCO 2023;Abstract LBA4500.
Hecht JR et al. STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC). Gastrointestinal Cancers Symposium 2023;Abstract TPS267.
Johns A et al. CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC). ASCO 2023;Abstract 4597.
Labaki C et al. Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). ASCO 2023;Abstract 4519.
Lee C-H et al. First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study. ASCO 2023;Abstract 4518.
Lee C-H et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial. ASCO 2023;Abstract 4537.
Lee CH et al. Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol 2022;40(21):2333-41. Abstract
McGregor BA et al. Phase II study of cabozantinib (cabo) with nivolumab (nivo) and ipilimumab (ipi) in advanced renal cell carcinoma with variant histologies (RCCvh). ASCO 2023;Abstract 4520.
Meza L et al. Tivozanib in patients with advanced renal cell carcinoma previously treated with axitinib: Subgroup analysis from TIVO-3. Oncologist 2023;28(3):e167-70. Abstract
Motzer RJ et al. Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial. ASCO 2023;Abstract 4506.
Motzer RJ et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). ASCO 2023;Abstract 4502.
Motzer RJ et al. Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial. ESMO 2022;Abstract LBA4.
Motzer RJ et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277-90. Abstract
Pal SK et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): A multicentre, randomised, double-blind, phase 3 trial. Lancet 2022;400(10358):1103-16. Abstract
Porta CG et al. Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study. ESMO 2022;Abstract 1449MO.
Rini BI et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. ASCO 2023;Abstract LBA4501.
Tripathi A et al. Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial. ASCO 2023;Abstract 4562.